Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) - Seino, Y; Min, K W; Niemoeller, E; Takami, A (Diabetes Obes Metab, 2012)